Significant Revenue Growth
Camurus reported SEK 567 million in revenue for the quarter, reflecting an 8% increase compared to the same period last year, with year-to-date revenue growth of 37%.
Strong Profitability
The company's profit before tax was SEK 245 million, representing a 43% profit margin in the quarter and a 48% increase in profit compared to the same period last year.
Brixadi Sales Surge
Brixadi sales in the U.S. generated SEK 111 million in royalty income for the quarter, up 91% compared to the same period last year and a 25% increase from the previous quarter.
Positive R&D Developments
Marketing approvals for Oczyesa were received in the U.K., and Camurus was granted 2 new orphan drug designations of CAM2029 in autosomal dominant polycystic kidney disease.
Cash Position Improvement
Camurus increased its cash position by SEK 167 million, resulting in a net cash position of SEK 3.5 billion, which is an increase of 28% compared to last year.